149 results about "Adhd symptoms" patented technology

Described are methods, devices, and systems for a novel, inexpensive, easy to use therapy for treatment of coma, post-traumatic stress disorder, Parkinson's disease, cognitive performance, and/or amblyopia. Described are methods and devices to treat coma, post-traumatic stress disorder, Parkinson's disease, cognitive performance, and/or amblyopia that involves no medication. Methods and devices described herein use alternating magnetic fields to gently “tune” the brain and affect symptoms of coma, post-traumatic stress disorder, Parkinson's disease, cognitive performance, and/or amblyopia.

Computer eyewear for reducing the effects of Computer Vision Syndrome (CVS). In one embodiment, the eyewear comprises a frame and two lenses. In some embodiments, the frame and lenses have a wrap-around design to reduce air flow in the vicinity of the eyes. The lenses can have optical power in the range of approximately +0.5 to +2.5 diopters for reducing accommodation demands on a user's eyes when using a computer. The lenses can also include prismatic power for reducing convergence demand on a user's eyes when sitting at a computer. The lenses can also include a partially transmissive mirror coating, tinting, and anti-reflective coatings. In one embodiment, a partially transmissive mirror coating or tinting spectrally filters light to remove spectral peaks in fluorescent or incandescent lighting.

The present invention relates to compositions and methods of alleviating a symptom of sleep apnea, snoring associated with and independent of sleep apnea, and/or sudden infant death syndrome by administering oxytocin. Specifically, the invention includes a method of administering oxytocin or a salt thereof to an animal in order to treat obstructive sleep apnea, snoring associated with and independent of sleep apnea, and sudden infant death syndrome.

The invention discloses a quantization evaluating device and method for dyskinesia symptoms of Parkinson and related extrapyramidal diseases. The device comprises an S-shaped gait channel, a finger inertia element node, a body inertia element node, a high-speed image collection unit, a central computer, an inertia element synchronization box, a synchronization state lamp, a wireless router, a switch and a power supply. The method comprises the steps of starting initialization of devices and starting the devices, adding basic information of testing personnel or searching existing testing personnel, selecting a collection mode, synchronizing a data collection unit module, collecting, displaying and storing data under assigned actions in real time, analyzing the data, and storing and printing quantization evaluating results. According to the quantization evaluating device and method for the dyskinesia symptoms of the Parkinson and related extrapyramidal diseases, the subjective evaluating method depending on the experiment of clinicians is thoroughly changed, and the device and method have improved theoretical value and realistic guidance significance on treatment of patients with dyskinesia, making of rehabilitation schemes and judgment of the curative effect and a prognosis.

S-alkylsiothiouronium derivatives such as S-ethylisothiouronium diethylphosphate are used for the treatment of headaches, in particular, migraines, as well as for the prevention or treatment of nausea and vomiting. The compositions of the invention are also effective in preventing or alleviating emesis associated with migraines or other medical conditions such as chemotherapy or radiotherapy, as well as other symptoms of migraines including phonophobia and photophobia.

Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.

A method and system for medical imaging of neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD), autism, and schizophrenia. Noninvasive, in vivo methods identify novel brain molecular biomarkers of normal neurodevelopment in order to determine molecular underpinnings of abnormal neurodevelopment. The described brain molecular biomarkers will aid in the presymptomatic diagnosis of neuropsychiatric disorders which begin in childhood and adolescence, such as ADHD, autism, and schizophrenia.

The present invention relates to the treatment of compulsive, impulsive and pervasive developmental disorders. More particularly, the methods described herein comprise administration of memantine to an individual suffering from such a disorder in an amount effective to relieve one or more symptoms of said disorder. In particularly preferred aspects, the invention is directed to the use of memantine for the treatment of autism

Methods and apparatus are provided to prevent, treat, and cure chemotherapy induced nausea in human beings. The inhalation of an effective amount of vaporized essential oil from Mentha piperita (peppermint oil) has been shown in practice to prevent, treat, and cure chemotherapy induced nausea. A simple hand-held apparatus provides the vapors to be inhaled through the nostril to prevent, treat, and cure chemotherapy induced nausea.

This invention pertains to the discovery that brain-derived neurotrophic factor (BDNF) and its associated signaling pathway is involved in reversing and/or counteracting neuroadaptations within the mesolimbic system that contribute to the development and/or maintenance of addiction (e.g. alcohol addiction). This invention also pertains to the discovery that ibogaine activity is mediated by changes in mRNA expression of GDNF. Thus, in certain embodiments, this inventioni provides a method of mitigating one or more symptoms of substance abuse in a mammal by increasing the expression or activity of GDNF, BDNF, RACK1, and/or the dopamine D3 receptor (D3R) in said mammal.

Dietary supplements, compositions and methods of administering the supplements to reduce pain, inflammation and stiffness in said mammal within a few hours. The supplements and compositions can include a combination of an amino acid, vitamins, herbs and enzymes. The composition/supplement can be put in capsule form and when administered to mammals can reduce these symptoms with approximately two hours. reducing the pain and inflammation associated with chronic joint discomfort, chronic low back pain, muscle strain, arthritis, sports injuries, normal everyday bumps and bruises. The novel composition has also been shown to be very effective in reducing monthly menstrual symptoms (PMS). The novel composition can also have benefits for other ailments such as but not limited to Osteoarthritis, Cardiovascular disease, Neurological ailments, Alzheimer disease, and Cancer.

Provided are methods of treating a patient diagnosed with post-traumatic stress disorder, by administering to the patient a therapeutically effective amount of Compound A. Also provided are methods of improving resilience in a patient by administering a therapeutically effective amount of Compound A. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of Compound A and assessing at least one of sign, symptom, or symptom cluster of post-traumatic stress disorder; and diagnosing post-traumatic stress disorder in the patient if the Compound A reduces at least one of sign, symptom, and symptom cluster of post-traumatic stress disorder.

The present invention provides methods and compositions for reducing visceral fat by administering to the subject a therapeutically effective amount of a compound that increases the bioactive serum levels of insulin-like growth factor-1 (IGF-1) in the subject, thereby ameliorating negative effects of visceral obesity. The invention is useful in the treatment, prevention, or amelioration of one or more symptoms of visceral obesity or IGF-1 deficiency related condition, including, for example, cardiovascular disease and the metabolic syndrome.

Described herein are inventions is directed to methods of treating a cardiac dysfunction and symptoms of cardiac dysfunction in a subject that includes administering an amount of probenecid effective to treat a symptom of cardiac dysfunction. The probenecid may be administered in at least one of an injection, orally, or transdermally. The amount of probenecid is sufficient to result in an improved performance on a standardized 6 minute walk test, an improved New York Heart Association (NYHA) classification, a lower diuretic dose requirement, a lower serum BNP levels, a normalization of serum sodium concentrations, and combinations thereof In an embodiment, probenecid is administered over a period of about 8 hours to about 24 hours. Probenecid may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years. Probenecid may be administered in an amount sufficient to treat the symptoms of cardiac dysfunction.

This invention is directed to an Aromatherapy compound to combat symptoms of Premenstrual Syndrome. It uniquely comprises an externally applied compound consisting of "essential oils" (highly concentrated oils extracted from plant cells for use in natural, therapeutic applications) that aid in the relief or reduction of symptoms of PMS. The compound preferably comprises equal proportions of essential oil of geranium, essential oil of clary sage, and essential oil of orange. The compound can be used "neat" (directly on the skin), however, the preferred embodiment is to add the compound to a "carrier" (a base for diluting the Aromatherapy compound) such as lotion or vegetable oil. The preferred formula is approximately 3 milliliters essential oil (1milliliter of geranium, 1 milliliter of clary sage, and 1 milliliter of orange) blended in 120 milliliters of carrier.

The present invention is directed to a device and method for monitoring and assessment of movement disorder symptoms. The device and method disclosed herein are particularly amenable to remote monitoring of a subject's movement disorder symptoms. Briefly stated, in certain preferred embodiments of the present invention the movement disorder monitoring device accompanies a subject to a remote location where the device is used to record data relating to the severity of a subject's movement disorder symptoms over a period of time. This data is then subsequently used by physicians or other clinicians in optimizing and assessing treatment options directed at alleviating a subject's movement disorder symptoms. The method and device of the present invention can be used to monitor symptoms of a number of movement disorders including but not limited to dystonia, essential tremor, Huntington's disease, various ataxias, multiple sclerosis, psychogenic tremor, and Parkinson's disease.